Yibin Yang

9PUBLICATIONS
30CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 13, 2026
PLK1 inhibition enhances Brentuximab vedotin efficacy in CD30-positive T-cell lymphoma via spindle assembly checkpoint activation.

|Nov 12, 2025
The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma.

Wei Wei, Zhihui Song, Yajun Wang

|Nov 10, 2025
Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.

Keito Suto, Norio Takei, Keito Yokoyama

|Oct 21, 2024
Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.

Keito Suto, Norio Takei, Keito Yokoyama

|Jan 08, 2024
Targeting DHX9 Triggers Tumor-Intrinsic Interferon Response and Replication Stress in Small Cell Lung Cancer.

Takahiko Murayama, Jun Nakayama, Xinpei Jiang

|Dec 24, 2023
Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma.

Masahiro Chiba, Joji Shimono, Keito Suto

Pageof 2

Frequent Collaborators

7 joint publications

Masao Nakagawa

5 joint publications

Masahiro Chiba

4 joint publications

Wei Wei

4 joint publications

Keito Suto